Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The disposition of a number of drugs has been reported to be altered in patients with Cystic
Fibrosis (CF). Changes in pharmacokinetic parameters observed included increased volumes of
distribution and increased clearance of renally eliminated drugs. The purpose of this this
study is to characterize the pharmacokinetics of IV lansoprazole and its metabolites in
normal healthy children and children with Cystic Fibrosis (CF) ages 2 to < 10 years. It is
suspected that children with CF will have a more rapid clearance as compared to healthy
children.